A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Exclusion Criteria

• •1. Other active malignancies within 5 years or at the same time;
• •2. Local antitumor therapy was received within 4 weeks prior to initiation of treatment;
• •3. Subjects with biliary obstruction should be excluded;
• •4. There is active autoimmune disease or a history of autoimmune disease that may recur;
• •5. Known or suspected history of interstitial pneumonia or interstitial lung disease, or prior history of interstitial pneumonia or interstitial lung disease requiring hormone therapy;
• •6. Severe infection within 4 weeks prior to initiation of study treatment;
• •7. Active hepatitis B virus (HBV) infection;
• •8. Have serious cardiovascular and cerebrovascular diseases.